Internal Medicine, Pulmonary Disease · Austin, TX
NPI
1972687127
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
1301 W 38th St Ste 514
Austin, TX, 78705
Phone (512) 681-0500
Groups this clinician bills Medicare through
Medicare paid, 2024
$42K
480 services
Medicare patients, 2024
168
Average age 74
Drug cost, 2024
$14.2M
1,615 prescriptions
Company payments, 2025
$14K
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John D Dallas was code 99214 (office e&m - established), 131 times for 72 patients. In total John D Dallas billed 480 services in 30 codes, and Medicare paid $42K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 131 | 72 | $69.26 | $9,073 |
| 99291 Critical Care E&M | Facility | 70 | 35 | $165.21 | $12K |
| 99232 Hospital E&M - Subsequent | Facility | 57 | 35 | $61.58 | $3,510 |
| 99233 Hospital E&M - Subsequent | Facility | 48 | 26 | $92.73 | $4,451 |
| 94618 Pulmonary Function Testing | Facility | 43 | 22 | $15.24 | $655 |
| 99215 Office E&M - Established | Facility | 30 | 18 | $102.86 | $3,086 |
| 36620 Vascular | Facility | 11 | 11 | $30.96 | $341 |
By year: 2022 $47K for 556 services; 2023 $44K for 475 services; 2024 $42K for 480 services.
Medicare prescription drug claims, 2024
In 2024, the drug John D Dallas prescribed most often to Medicare patients was Opsumit (Macitentan), with 352 prescriptions and refills. In total John D Dallas wrote 1,615 Medicare prescriptions that cost $14.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Opsumit Macitentan | 352 | 360 | 34 | $4.5M |
| Tadalafil Generic | 243 | 267 | 30 | $197K |
| Uptravi Selexipag | 185 | 185 | 17 | $4.0M |
| Winrevair Sotatercept-Csrk | 102 | 102 | 16 | $2.0M |
| Furosemide Generic | 87 | 143 | 25 | $501 |
| Adempas Riociguat | 83 | 83 | Under 11 | $1.1M |
| Potassium Chloride Generic | 82 | 129 | 19 | $2,423 |
| Ambrisentan Generic | 56 | 72 | Under 11 | $278K |
| Spironolactone Generic | 53 | 90 | 12 | $592 |
| Ofev Nintedanib Esylate | 35 | 35 | Under 11 | $452K |
| Tyvaso Dpi Treprostinil | 29 | 29 | Under 11 | $648K |
| Orenitram Er Treprostinil Diolamine | 23 | 23 | Under 11 | $590K |
| Torsemide Generic | 23 | 39 | Under 11 | $1,060 |
| Adcirca Tadalafil | 22 | 22 | Under 11 | $85K |
| Sildenafil Citrate Generic | 21 | 21 | Under 11 | $5,400 |
Brand drugs: 947 claims; generic drugs: 668 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John D Dallas $14K ($14K in general payments such as food, travel and fees) from 2 companies. The largest payer was Actelion Pharmaceuticals US, Inc. with $14K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.